AnGes Inc - ESG Rating & Company Profile powered by AI
Check the bottom of the webpage for potential risks for AnGes Inc based on industry, geography and size. The ESG score for AnGes Inc indicates the company's transparency towards the United Nations Sustainable Development Goals. Alternative corporations in the rating industry group for AnGes Inc are shownin the table.
AnGes Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.7; made up of an environmental score of 8.0, social score of 8.0 and governance score of 4.0.
6.7
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 432 | Twist Bioscience Corp | 6.8 | High |
| 432 | Rhythm Pharmaceuticals Inc | 6.8 | High |
| 446 | AnGes Inc | 6.7 | High |
| 446 | Actinium Pharmaceuticals Inc | 6.7 | High |
| 446 | Atara Biotherapeutics Inc | 6.7 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does AnGes Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes AnGes Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes AnGes Inc report the average age of the workforce?
Sign up for free to unlockDoes AnGes Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes AnGes Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes AnGes Inc disclose cybersecurity risks?
Sign up for free to unlockDoes AnGes Inc offer flexible work?
Sign up for free to unlockDoes AnGes Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes AnGes Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes AnGes Inc conduct supply chain audits?
Sign up for free to unlockDoes AnGes Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes AnGes Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes AnGes Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes AnGes Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes AnGes Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes AnGes Inc disclose water use targets?
Sign up for free to unlockDoes AnGes Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid AnGes Inc have a product recall in the last two years?
Sign up for free to unlockDoes AnGes Inc disclose incidents of discrimination?
Sign up for free to unlockDoes AnGes Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas AnGes Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes AnGes Inc disclose parental leave metrics?
Sign up for free to unlockDoes AnGes Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes AnGes Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes AnGes Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes AnGes Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes AnGes Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes AnGes Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs AnGes Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes AnGes Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes AnGes Inc disclose its waste policy?
Sign up for free to unlockDoes AnGes Inc report according to TCFD requirements?
Sign up for free to unlockDoes AnGes Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes AnGes Inc disclose energy use targets?
Sign up for free to unlockDoes AnGes Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes AnGes Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for AnGes Inc
These potential risks are based on the size, segment and geographies of the company.
AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products. Its lead product is Hepatocyte Growth Factor (HGF) Plasmid, a gene therapy for the treatment of critical limb ischemia, a serious impairment of blood circulation in the leg. The company is also developing NF-kB Decoy Oligonucleotide, a nucleic acid medicine that suppresses inflammation for diseases, including low back pain; drugs for treating atopic dermatitis and disc degeneration; medical devices for the prevention of vascular restenosis; cervical intraepithelial neoplasia therapeutic vaccines for cervical cancer; and DNA vaccines for high blood pressure through collaborative research agreement with Osaka University. AnGes, Inc. has alliances with BioMarin Pharmaceutical Inc. to market Naglazyme, a drug for the treatment of mucopolysaccharidosis VI in Japan; and Mitsubishi Tanabe Pharma Corporation for marketing HGF Plasmid for the treatment of peripheral arterial disease in the United States and Japan. It also has alliances with SHIONOGI & CO., LTD. for the marketing of drugs for external use containing NF-kB decoy oligonucleotide for skin diseases; Vical, Inc. for the development and marketing of Allovectin for cancer treatment; and Osaka University to develop a coronavirus vaccine. In addition, the company has a collaboration agreement with Brickell Biotech, Inc. to develop investigational plasmid DNA vaccine intended to prevent coronavirus in the United States, South America, and other markets. The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was founded in 1999 and is headquartered in Ibaraki, Japan.